Single injection of novel kappa opioid receptor agonist salvinorin A attenuates expression of cocaine induced behavioral sensitization in rats

View/ Open
Issue Date
2012-04Author
Morani, Aashish S.
Schenk, Susan
Prisinzano, Thomas E.
Kivell, Bronwyn
Publisher
Lippincott, Williams & Wilkins
Type
Article
Article Version
Scholarly/refereed, author accepted manuscript
Rights
© 2012 Lippincott Williams & Wilkins, Inc.
Metadata
Show full item recordAbstract
Kappa opioid receptor (KOPr) activation antagonizes many cocaine-related behaviors but adverse
side effects such as sedation, dysphoria and depression limit their therapeutic use. Recently,
salvinorin A (Sal A), a naturally occurring KOPr agonist, has been shown to attenuate cocaineinduced
drug-seeking in a model of relapse in rats. The present study evaluated the effects of acute
Sal A exposure on cocaine-induced hyperactivity and cocaine sensitization in rats. Acute treatment
with the dose of Sal A that decreased drug-seeking in a previous study (0.3 mg/kg), significantly
attenuated the expression of cocaine sensitization. This dose of Sal A failed to affect spontaneous
locomotion or to produce a conditioned taste aversion to a novel-tasting saccharin solution.
However, Sal A decreased climbing and swimming time and increased time spent immobile in the
forced swim test. These findings indicate that Sal A, just like traditional KOPr agonists, attenuates
cocaine-induced behavioral sensitization but does not produce the adverse effect of conditioned
aversion, suggesting improved potential compliance. However, pro-depressive effects were also
produced and these effects may limit the therapeutic potential.
Collections
Citation
Morani, A. S., Schenk, S., Prisinzano, T. E., & Kivell, B. (2012). Single injection of novel kappa opioid receptor agonist salvinorin A attenuates expression of cocaine induced behavioral sensitization in rats. Behavioural Pharmacology, 23(2), 162–170. http://doi.org/10.1097/FBP.0b013e3283512c1e
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.